300558 贝达药业
午间休市 10-21 11:30:00
资讯
新帖
简况
贝达药业最新公告：注射用BPI-585771临床试验申请获受理
证券之星 · 10-20 19:20
贝达药业最新公告：注射用BPI-585771临床试验申请获受理
贝达药业“眼科梦”再遇挫！两项Ⅲ期临床试验失利，合作方美股单日暴跌超85%
红星资本局 · 10-20 18:44
贝达药业“眼科梦”再遇挫！两项Ⅲ期临床试验失利，合作方美股单日暴跌超85%
伏罗尼布眼科管线再遭挫折，贝达药业面临减值压力
蓝鲸财经 · 10-20 17:27
伏罗尼布眼科管线再遭挫折，贝达药业面临减值压力
美方合作公司单日暴跌85%，贝达药业又有利空，开盘大跌
同花顺 · 10-20 11:16
美方合作公司单日暴跌85%，贝达药业又有利空，开盘大跌
股市必读：贝达药业新发布《关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二项关键Ⅲ期临床试验数据的公告》
证券之星 · 10-20 00:56
股市必读：贝达药业新发布《关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二项关键Ⅲ期临床试验数据的公告》
贝达药业最新公告：合作伙伴的伏罗尼布眼科制剂三期临床试验未达主要终点公司将对伏罗尼布资产组开展减值测试
证券之星 · 10-19 21:00
贝达药业最新公告：合作伙伴的伏罗尼布眼科制剂三期临床试验未达主要终点公司将对伏罗尼布资产组开展减值测试
贝达药业：合作伙伴的DURAVYU治疗wAMD三期临床试验未达主要终点 公司将对伏罗尼布资产组开展减值测试
格隆汇 · 10-19 20:57
贝达药业：合作伙伴的DURAVYU治疗wAMD三期临床试验未达主要终点 公司将对伏罗尼布资产组开展减值测试
股市必读：贝达药业新发布《关于BPI-572270胶囊药品联用临床试验申请获得受理的公告》
证券之星 · 10-19 03:42
股市必读：贝达药业新发布《关于BPI-572270胶囊药品联用临床试验申请获得受理的公告》
贝达药业最新公告：BPI-572270胶囊药品联用临床试验申请获得受理
证券之星 · 10-16
贝达药业最新公告：BPI-572270胶囊药品联用临床试验申请获得受理
贝达药业（300558）10月12日主力资金净卖出1702.74万元
证券之星 · 10-13
贝达药业（300558）10月12日主力资金净卖出1702.74万元
10月8日贝达药业跌5.21%，富国精准医疗混合A基金重仓该股
证券之星 · 10-08
10月8日贝达药业跌5.21%，富国精准医疗混合A基金重仓该股
贝达药业（300558）9月30日主力资金净卖出1035.26万元
证券之星 · 10-08
贝达药业（300558）9月30日主力资金净卖出1035.26万元
贝达药业：BPI-572270胶囊获美国FDA新药临床试验批准
同花顺 · 10-07
贝达药业：BPI-572270胶囊获美国FDA新药临床试验批准
贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验
智通财经 · 09-28
贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验
贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床
格隆汇 · 09-28
贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床
贝达药业（300558）9月24日主力资金净卖出6821.79万元
证券之星 · 09-28
贝达药业（300558）9月24日主力资金净卖出6821.79万元
贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展
证券之星 · 09-24
贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展
贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制
证券之星 · 09-24
贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制
贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%
证券之星 · 09-24
贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%
贝达药业：取得FRSW117在中国独家经销权
证券之星 · 09-24
贝达药业：取得FRSW117在中国独家经销权
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":42.4,"timestamp":1792554669000,"preClose":41.83,"halted":0,"volume":4350629,"delay":0,"changeRate":0.0136,"floatShares":422000000,"shares":423000000,"eps":1.1045,"marketStatus":"午间休市","change":0.57,"latestTime":"10-21 11:30:00","open":41.84,"high":42.64,"low":41.74,"amount":184000000,"amplitude":0.0215,"askPrice":42.4,"askSize":52,"bidPrice":42.39,"bidSize":64,"shortable":0,"etf":0,"ttmEps":1.1045,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792558800000},"marketStatusCode":3,"adr":0,"adjPreClose":41.83,"symbolType":"stock","openAndCloseTimeList":[[1792546200000,1792553400000],[1792558800000,1792566000000]],"highLimit":46.01,"lowLimit":37.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423331685,"isCdr":false,"pbRate":2.67,"roa":"--","peRate":38.388411,"roe":"4.61%","epsLYR":0.73,"committee":-0.004016,"marketValue":17949000000,"turnoverRate":0.0103,"status":0,"floatMarketCap":17900000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2676280660","title":"贝达药业最新公告：注射用BPI-585771临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676280660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676280660?lang=zh_cn&edition=full","pubTime":"2026-10-20 19:20","pubTimestamp":1792495235,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司收到国家药品监督管理局签发的《受理通知书》，申报的注射用BPI-585771拟用于治疗晚期实体瘤的药物临床试验申请已获受理。该药物为公司自主研发的靶向多种KRAS突变体的新型PROTAC降解剂，可同时结合激活态和失活态KRAS，诱导其泛素化并经蛋白酶体降解，抑制下游信号通路并诱导肿瘤细胞凋亡。目前多款KRASPROTAC降解剂处于临床开发阶段，该药物短期内对公司营收不会产生大的影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000031197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676667127","title":"贝达药业“眼科梦”再遇挫！两项Ⅲ期临床试验失利，合作方美股单日暴跌超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676667127","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676667127?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:44","pubTimestamp":1792493050,"startTime":"0","endTime":"0","summary":"红星资本局10月20日消息今日，贝达药业（300558.SZ）股价开盘大跌超8%，之后跌幅逐渐收窄。截至发稿，贝达药业跌0.43%，报41.83元/股，总市值177.08亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610203901450162.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610203901450162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","PSYK","BK0060","MDTX","300558","BK0239","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676694436","title":"伏罗尼布眼科管线再遭挫折，贝达药业面临减值压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2676694436","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676694436?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:27","pubTimestamp":1792488450,"startTime":"0","endTime":"0","summary":"消息公布后，贝达药业宣布将对伏罗尼布相关资产组开展减值测试，可能对当期净利润产生一定影响。贝达药业公告指出，截至公告日，已就授权EyePoint开发伏罗尼布眼科适应症收到首付款及里程碑付款合计600万美元，且根据协议约定无需返还。在此前2026年半年报中，贝达药业已因LUGANO试验失败计提了商誉减值准备。此次LUCIA再度失败，意味着相关资产组的可收回金额需要进一步下调，减值风险尚未出清。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792488307277151783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676655437","title":"美方合作公司单日暴跌85%，贝达药业又有利空，开盘大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2676655437","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676655437?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:16","pubTimestamp":1792466160,"startTime":"0","endTime":"0","summary":"【导读】贝达药业公告，其合作伙伴EyePoint的在研伏罗尼布眼科制剂DURAVYU的第二项关键Ⅲ期临床试验未达预设主要终点10月20日早盘，贝达药业股价开盘大跌超8%。贝达药业10月19日晚公告，公 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261020/c680871034.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261020/c680871034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676409680","title":"股市必读：贝达药业新发布《关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二项关键Ⅲ期临床试验数据的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676409680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676409680?lang=zh_cn&edition=full","pubTime":"2026-10-20 00:56","pubTimestamp":1792428970,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，贝达药业报收于42.01元，下跌0.02%，换手率2.13%，成交量8.98万手，成交额3.75亿元。公司公告汇总关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二项关键Ⅲ期临床试验数据的公告贝达药业公告其合作伙伴EyePoint公布的DURAVYU治疗湿性年龄相关性黄斑变性Ⅲ期临床试验LUCIA研究未达到主要终点，即在最佳矫正视力变化方面未显示相对于阿柏西普的非劣效性。EyePoint将分析数据以评估后续研发方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000001530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676686097","title":"贝达药业最新公告：合作伙伴的伏罗尼布眼科制剂三期临床试验未达主要终点公司将对伏罗尼布资产组开展减值测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2676686097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676686097?lang=zh_cn&edition=full","pubTime":"2026-10-19 21:00","pubTimestamp":1792414851,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司合作伙伴EyePoint公布其在研伏罗尼布眼科制剂EYP-1901玻璃体内植入剂（DURAVYU）治疗湿性年龄相关性黄斑变性（简称“wAMD”）第二项关键Ⅲ期临床试验LUCIA数据，该研究未达到预设主要终点，未能证明相对于阿柏西普2mg对照组的统计学非劣效性。关键次要终点均已达成。公司将对伏罗尼布相关资产组开展减值测试，可能对当期净利润产生一定影响。该产品尚处临床试验阶段，未实现商业化销售，本次临床结果不会对当前生产经营产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900028332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676686472","title":"贝达药业：合作伙伴的DURAVYU治疗wAMD三期临床试验未达主要终点 公司将对伏罗尼布资产组开展减值测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2676686472","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676686472?lang=zh_cn&edition=full","pubTime":"2026-10-19 20:57","pubTimestamp":1792414649,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676657348","title":"股市必读：贝达药业新发布《关于BPI-572270胶囊药品联用临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676657348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676657348?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:42","pubTimestamp":1792352531,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，贝达药业报收于42.02元，上涨0.07%，换手率3.03%，成交量12.8万手，成交额5.52亿元。公司公告汇总：贝达药业全资子公司申报的BPI-572270胶囊多项联合用药临床试验申请获国家药监局受理。该药物为自主研发的泛RAS“非降解型分子胶”抑制剂，拟联合化疗、PD-1/VEGF双抗、PD-1单抗+含铂化疗、FAK抑制剂、EGFR抗体等方案治疗晚期实体瘤，评估其安全性、耐受性、药代动力学及初步有效性。此前该药已获中国、美国、澳大利亚临床试验批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675560781","title":"贝达药业最新公告：BPI-572270胶囊药品联用临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675560781","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675560781?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:21","pubTimestamp":1792142480,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司全资子公司景曜生物申报的BPI-572270胶囊分别联合化疗、PD-1/VEGF双抗、PD-1单抗+含铂化疗、FAK抑制剂、EGFR抗体等多种治疗方案的药物临床试验申请已获国家药监局受理。该药为新型强效泛RAS“非降解型分子胶”抑制剂，拟探索与不同机制抗肿瘤药物联合用于晚期实体瘤治疗。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600029205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675389708","title":"贝达药业（300558）10月12日主力资金净卖出1702.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675389708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675389708?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:20","pubTimestamp":1791854407,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月12日收盘，贝达药业报收于46.15元，下跌4.71%，换手率2.43%，成交量10.25万手，成交额4.83亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入4465.08万元，融资偿还3346.91万元，融资净买入1118.18万元，连续3日净买入累计8802.07万元。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300008597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027169","title":"10月8日贝达药业跌5.21%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027169?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:47","pubTimestamp":1791449254,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日贝达药业跌5.21%，收盘报47.85元，换手率3.95%，成交量16.67万手，成交额8.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.2487，较上一交易日上涨2.6%，近一年下跌8.34%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673490690","title":"贝达药业（300558）9月30日主力资金净卖出1035.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673490690","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673490690?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:06","pubTimestamp":1791421604,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，贝达药业报收于50.48元，上涨3.1%，换手率4.49%，成交量18.94万手，成交额9.52亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入5633.23万元，融资偿还6903.1万元，融资净偿还1269.88万元。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673099663","title":"贝达药业：BPI-572270胶囊获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673099663","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673099663?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:46","pubTimestamp":1791362760,"startTime":"0","endTime":"0","summary":"人民财讯10月7日电，贝达药业(300558)10月7日公告，公司全资子公司景曜生物申报的BPI-572270胶囊药品临床试验申请获得美国FDA批准。该药品拟用于晚期实体瘤。 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261007/c680447508.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261007/c680447508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4588","LABU","BK0239","IBBQ","PSYK","300558","BK4585","MDTX","BK0060","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670323311","title":"贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2670323311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670323311?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:28","pubTimestamp":1790587693,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，公司全资子公司杭州景曜生物科技有限责任公司(以下简称“景曜生物”)申报的BPI-572270胶囊用于携带特定RAS突变的晚期实体瘤患者的I/Ⅱ期临床研究已获得澳大利亚人类研究伦理委员会(HumanResearch Ethics Committee，以下简称“HREC”)的审查批准，并完成澳大利亚药品管理局(简称“TGA”)临床试验备案，这是公司首款在澳大利亚获批开展临床试验的新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558","IBBQ","BK0060","PSYK","IBBJ","BK0239","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670095280","title":"贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2670095280","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670095280?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:50","pubTimestamp":1790585449,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670077624","title":"贝达药业（300558）9月24日主力资金净卖出6821.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670077624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670077624?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:24","pubTimestamp":1790558662,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，贝达药业报收于48.23元，下跌4.23%，换手率2.08%，成交量8.76万手，成交额4.29亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入3225.1万元，融资偿还4631.04万元，融资净偿还1405.95万元。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800002935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498050","title":"贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669498050?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:51","pubTimestamp":1790254294,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。请问董秘，公司如何契合这一规划，使贝达药业在创新发展和年营收方面达到目标？公司将坚持\"自主研发、战略合作、市场销售、创新生态圈\"四驾马车协同发展，持续完善\"研发投入－产品商业化－收益再投入\"的良性循环机制，不断提升创新研发与产业化能力，并坚持国际化发展战略，持续推进创新药开发与商业化，推动公司长期稳定发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669450428","title":"贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制","url":"https://stock-news.laohu8.com/highlight/detail?id=2669450428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669450428?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236111,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558","399001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669245047","title":"贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669245047","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669245047?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236111,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，纵观贵公司2026年中报数据，公司9款商业化产品，为何营业收入不到同行业艾某斯1款产品的六成，净利润也不到其两成？2026年上半年，公司实现营业收入19.76亿元，同比增长14.12%；实现归属于上市公司股东的净利润3.02亿元，同比增长115.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669845040","title":"贝达药业：取得FRSW117在中国独家经销权","url":"https://stock-news.laohu8.com/highlight/detail?id=2669845040","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669845040?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236109,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。2025年，公司与晟斯生物达成战略合作，并取得注射用培重组人凝血因子VIII-Fc融合蛋白在中国的独家经销权，目前FRSW117的上市申请已获受理，正处于审评阶段。晟斯生物在长效生长激素的研究领域已有布局和探索，公司将充分发挥生态圈企业的科研协同，加快推进新药的开发和产业化。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792554686015,"stockEarnings":[{"period":"1week","weight":-0.0719},{"period":"1month","weight":-0.1141},{"period":"3month","weight":-0.311},{"period":"6month","weight":-0.1591},{"period":"1year","weight":-0.2677},{"period":"ytd","weight":-0.1013}],"compareEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0874},{"period":"1year","weight":-0.0333},{"period":"ytd","weight":-0.0588}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"50981人(较上一季度增加19.47%)","perCapita":"8281股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42333万元","survey":" 贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}